alternative titration semaglutide dosing regimens of GLP‐1 receptor agonists may reduce costs and maintain weight loss efficacy Switching between weight-loss medications -

Warning signs include: Trembling or shakiness Sweating and palpitations Confusion or difficulty concentrating Dizziness or light-headedness Hunger and irritability Pale skin and weakness In severe cases, hypoglycaemia can progress to loss of consciousness or seizures if left untreated

It also flags anyone taking ACE inhibitors, ARBs, or NSAIDs as facing heightened risk, since those also raise potassium

(2.3) Dosage Forms and Strengths Injection (3): o 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, 2.4 mg/0.75 mL, or 7.2 mg/0.75 mL (WEGOVY HD) in a single-dose pen o 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, or 2.4 mg/0.75 mL in a single-dose syringe o 9.6 mg/3 mL (3.2 mg/mL) solution in a single-patient-use pen (WEGOVY FlexTouch) that delivers four 2.4 mg/0.75 mL doses Tablets: 1.5 mg, 4 mg, 9 mg and 25 mg (3) Contraindications Warnings and Precautions Acute Pancreatitis: Has been observed in patients treated with GLP-1 receptor agonists, including WEGOVY

A doctor might prescribe it to a 16-year-old with obesity, based on their health